As Senior Director at Sanofi Vaccines External R&D, Sean is responsible for the identification and evaluation vaccine-related opportunities to support Sanofi Vaccines’ global pipeline strategy. Under his leadership, Sanofi Vaccines has completed three research agreements, initiated over 10 feasibility studies with both academic and industrial partners, organized 4 full due diligence, executed two global licensing agreements with biotech companies, and reached a 280 million AUD collaboration agreement with Queensland State Government. Sean has over 20 years of extensive vaccine R&D and business development experience. Before joining Sanofi, Sean was Co-Founder and Chief Operating Officer at Altravax from 2013 to 2015 and Executive Director & Head of the Vaccine Research Institute at Simcere Pharmaceutical Group from 2010 to 2013. Prior to Simcere, he worked as a Senior Scientist and Project Leader on multiple vaccine programs at Maxygen for 9 years. Sean received his Ph.D. degree in Biological Sciences from the University of Delaware, M.S degree in Microbiology from the Institute of Microbiology, Chinese Academy of Sciences, and B.S. degree in Microbiology from Shandong University. He received his postdoctoral training at Columbia University.

Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Professor Adrian V. S. Hill FRS is the Director and Founder of the Jenner Institute, and Mital Professor of Vaccinology at Oxford University. He is a passionate believer in the power of molecular medicine to address many of the most egregious health care inequities globally. His group have been leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in over eighty clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone.

His lab also designed a newly licensed high efficacy malaria vaccine, R21/Matrix-MTM, which has recently shown unprecedented high efficacy in a phase III trial in four African countries, again in partnership with the Serum Institute of India and also Novavax Inc. This vaccine promises to make a major impact on reducing the 500,000 childhood deaths from malaria each year. In 2021 he was elected a Fellow of the Royal Society and is a Knight Commander of the Order of the British Empire (KBE).

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).

Dr. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery.  His laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies.  His group has led the development of vaccine candidates for multiple pathogens of global significance, including HIV, Zika virus, tuberculosis, and most recently SARS-CoV-2.  His work contributed to the development of the Johnson & Johnson COVID-19 vaccine and the evaluation of multiple COVID-19 vaccines and monoclonal antibody therapeutics.  He was elected to the National Academy of Medicine in 2020 and received the King Faisal Prize in Medicine in 2023.

Dr. Berlanda Scorza is an accomplished pharmaceutical executive with a strong focus on translating scientific innovations into tangible patient benefits. He currently serves as Vice President of Global Health R&D Vaccines at GSK. Additionally, he is the Chairman of the Board and General Manager of the GSK Vaccines Institute for Global Health, as well as a member of the GSK Country Executive Board in Italy.

Before joining GSK in 2020, Dr. Berlanda Scorza held senior leadership roles at the Bill & Melinda Gates Foundation and PATH, where he led key programs focused on the development of seasonal and pandemic influenza vaccines.

Earlier in his career, Dr. Berlanda Scorza was a senior scientist at Chiron Corporation and Novartis Vaccines, where he contributed to the development of innovative vaccine technologies, including a replicon RNA vaccine, the cell-cultured influenza vaccine Flucelvax, and the bacterial vaccine platform GMMA. Dr. Berlanda Scorza earned his Ph.D. from the University of Milano-Bicocca and completed his post-doctoral research at Imperial College London.

Ruben Rizzi, physician by training, SVP of Global Regulatory Affairs at BioNTech. I joined the company in December 2019 just before the pandemic, and I have been the global regulatory lead for BioNTech for our COVID-19 development. Currently, I am still supporting the lifecycle of our COVID-19 vaccine, and I am co-leading the Global Regulatory Affairs department at BioNTech and working closely with the teams that are responsible for the development of BioNTech´s pipeline, post-approval activities and labelling

As Senior Director at Sanofi Vaccines External R&D, Sean is responsible for the identification and evaluation vaccine-related opportunities to support Sanofi Vaccines’ global pipeline strategy. Under his leadership, Sanofi Vaccines has completed three research agreements, initiated over 10 feasibility studies with both academic and industrial partners, organized 4 full due diligence, executed two global licensing agreements with biotech companies, and reached a 280 million AUD collaboration agreement with Queensland State Government. Sean has over 20 years of extensive vaccine R&D and business development experience. Before joining Sanofi, Sean was Co-Founder and Chief Operating Officer at Altravax from 2013 to 2015 and Executive Director & Head of the Vaccine Research Institute at Simcere Pharmaceutical Group from 2010 to 2013. Prior to Simcere, he worked as a Senior Scientist and Project Leader on multiple vaccine programs at Maxygen for 9 years. Sean received his Ph.D. degree in Biological Sciences from the University of Delaware, M.S degree in Microbiology from the Institute of Microbiology, Chinese Academy of Sciences, and B.S. degree in Microbiology from Shandong University. He received his postdoctoral training at Columbia University.

Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN.  Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.

Dr. Raman Rao joined as the Chief Executive Officer at Hilleman Laboratories in February 2020. Dr. Rao has more than two decades of experience in research and development, manufacturing and commercialisation of vaccines for infectious diseases in global pharma and biotech companies. Prior to joining Hilleman Laboratories, Dr. Rao served as the Vice President of Global Product Operations with Takeda, Singapore, where he enhanced the global product portfolio while successfully leading an international team across Japan, Singapore and the United States. The teams worked in the areas of dengue, norovirus, zika, polio and other vaccines.

Dr. Rao started his career in 2002 with Shantha Biotechnics Limited, part of Sanofi Aventis Group in India, in Clinical Research and Scientific Affairs. He holds a MD in Medical Microbiology from the Postgraduate Institute of Medical Education and Research.

He plans to carry forward Dr. Maurice Hilleman’s legacy for providing effective solutions for global health, especially those impacting low- and middle-income countries.

Dr. Hun Kim is the President of Global Business at SK Bioscience. His role is to oversee the company's product and platform portfolio in a comprehensive perspective from R&D to commercialization through global alliance and external innovation.

Dr. Hun Kim started his biopharmaceutical career in 1992 as a researcher at Green Cross Corporation, In 2000, he moved on to Berna Biotech, a part of Crucell at present. In 2008, he joined SK Chemicals,the parent company of SK Bioscience, and lead the company's expansion in vaccine R&D, Quality and manufacturing capabilities.

Under his oversight, the company developed and received approval for cell culture-based influenza vaccines (SKYCellflu/SKYCellflu Quadrivalent), varicella/herpes zoster vaccines (SKYVaricella/SKYZoster),and Pneumococcal Conjugation Vaccines. During the Pandemic, it successfully manufactured and supplied COVID-19 vaccines developed by AstraZeneca and NovaVax. With support from CEPI and BMGF, SK Bioscience also developed its own COVID-19 vaccine (SKYCovione), which became the first domestically developed COVID-19 vaccine to be approved in Korea.

Ms. WANG is responsible for the company's overall commercial operation in both China and Overseas markets. She has 23 years experience in pharmaceutical industry and holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. Jeanne joined the Company in 2012 and made outstanding achievements in multiple roles such as Head of HR, Head of Operation, Vice President of Strategy & Business Development and Chief Financial Officer. She helped the company set up the management system of financing, financial operations, human resources and commercialization. After completing several rounds of Pre-IPO fund raising, Ms. Wang also successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in 2020, making the Company the first “A+H” dual listing vaccine company.

主任医师，暨南大 学讲席教授。暨南大学疫苗产业研究院／疾病预防控制研究院院长。曾任中国疾控中心副主任。现在兼任中国卫生有害生物防制协会会长、中华预防医学会副会长，世界卫生组织病毒性肝炎防控委员会委员、西太区免疫接种技术委员会委员、世界公共卫生联盟执委、中华预防医学会医疗机构公共卫生管理分会主任委员等职务。

主要从事疫苗接种，传染病控制，慢性病危险因素监测和疾病负担研究。承担传染病防治科技重大专项“乙型肝炎病毒免疫预防新策略的研究”研究。作为第一作者和责任作者，分别在新英格兰杂志、柳叶刀和疫苗杂志发表多篇学术论文。

 获得了国务院特贴和卫生部有突出贡献中青年专家称号。2013年获得“吴阶平杨森医学药学奖”。2014年，“我国首次对甲型H1N1流感大流行有效防控及集成创新性研究”获得国家科技进步一等奖。2023年选为“广东省重大人才工程项目杰出人才”。2024年获广东省疾控中心高层次引进人才。

Dr. Berlanda Scorza is an accomplished pharmaceutical executive with a strong focus on translating scientific innovations into tangible patient benefits. He currently serves as Vice President of Global Health R&D Vaccines at GSK. Additionally, he is the Chairman of the Board and General Manager of the GSK Vaccines Institute for Global Health, as well as a member of the GSK Country Executive Board in Italy.

Before joining GSK in 2020, Dr. Berlanda Scorza held senior leadership roles at the Bill & Melinda Gates Foundation and PATH, where he led key programs focused on the development of seasonal and pandemic influenza vaccines.

Earlier in his career, Dr. Berlanda Scorza was a senior scientist at Chiron Corporation and Novartis Vaccines, where he contributed to the development of innovative vaccine technologies, including a replicon RNA vaccine, the cell-cultured influenza vaccine Flucelvax, and the bacterial vaccine platform GMMA. Dr. Berlanda Scorza earned his Ph.D. from the University of Milano-Bicocca and completed his post-doctoral research at Imperial College London.

Dr. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery.  His laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies.  His group has led the development of vaccine candidates for multiple pathogens of global significance, including HIV, Zika virus, tuberculosis, and most recently SARS-CoV-2.  His work contributed to the development of the Johnson & Johnson COVID-19 vaccine and the evaluation of multiple COVID-19 vaccines and monoclonal antibody therapeutics.  He was elected to the National Academy of Medicine in 2020 and received the King Faisal Prize in Medicine in 2023.

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).

Prof. Yuelong Shu

Director, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College. He is a member of the Chinese Academy of Medical Sciences and a Fellow of the American Academy of Microbiology. He was selected as the first batch of ‘National Science and Technology Innovation Leader’and‘2014 Top Ten Scientific and Technological Innovators’, and is the winner of National Science Fund for Distinguished Young Scholars and the China Youth Science and Technology Award. He has been honored with the National Science and Technology Progress Grand Prize, First Prize, Second Prize, the National Medical and Health System Advanced Individual, the National Innovation Award, the Public Health and Preventive Medicine Development Contribution Award, etc. He is currently the Chairman of the Branch of Medical Virology of the Chinese Medical Association and the Chairman of the Asia-Pacific Alliance for the Control of Influenza (APACI). He was the founding dean of the School of Public Health of Sun Yat-sen University (Shenzhen), the editor-in-chief of the Chinese Journal of Virology, the deputy director of the Institute of Viral Diseases of the Chinese Center for Disease Control and Prevention (CDC), the director of the National Influenza Center, and the director of the WHO Collaborating Center for Reference and Research on Influenza.

Shu has long focused on influenza prevention and control research, and has made outstanding achievements in the discovery of new viruses, the development of detection reagents, and the pathogenesis of infection. Through the systematic establishment of new influenza detection and surveillance technology, it was found for the first time in the world that a variety of new avian influenza viruses such as H7N9, H5N6 and H10N8 can lead to human infection and death; The first successful development of pandemic H1N1 2019 and H7N9 avian influenza detection reagent; The origin, evolution and infection mechanism of H7N9 and other avian influenza viruses were clarified, which provided key scientific and technological support for the successful prevention and control of the epidemic in China. He has published nearly 200 papers in Science, Nature, NEJM, Lancet and other academic journals as a corresponding author. The research results were selected as one of the ‘China’s 100 most influential international academic papers in 2013’and ‘2013 Top Ten Scientific Advances in China’.

Dr. Linfa Wang is a professor of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, and the inaugural executive director of PREPARE, Ministry of Health, Singapore. He is an international leader in the field of emerging zoonotic viruses and virus-host interaction. In response to the COVID-19 pandemic, he has served and is serving on multiple WHO committees for COVID-19, including the WHO IHR Emergency Committee. Prof. Wang has more than 500 scientific publications. He was the Editor-in-Chief for the Virology Journal from 2112-2022. Prof. Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2010, the American Academy of Microbiology in 2021 and the Australian Academy of Sciences in 2023. He received the Singapore President Science Award in 2021

Dr. Chen is a prominent scientist specializing in human vaccine research and antiviral therapies. He currently serves as the Chief Operating Officer at RuenHuei Biopharmaceuticals Inc., where he oversees the development and production of new vaccine candidates. Dr. Chen joined RH Biopharma in August 2018, bringing over a decade of practical industry experience in vaccine development. Before his role at RH Biopharma, Dr. Chen held several key positions at Adimmune Corporation, including the Director and Manager of the R&D Department. At Adimmune, he was instrumental in developing the EV71 vaccine and advancing a cell culture-based production process for influenza vaccines. Dr. Chen's academic background includes a Ph.D. from National Yang-Ming University in Taipei, Taiwan, where he specialized in Biochemistry and Molecular Biology. He also completed postdoctoral fellowships at the Genomics Research Center, Academia Sinica, and the Vollum Institute at Oregon Health and Science University in the United States. His research has significantly contributed to the field of vaccine development, particularly in creating more effective influenza vaccines and understanding the immune responses to viral infections. He is currently also special technical expert at the Department of Pharmacy at National Taiwan University and an associate professor at the Department of Chemistry at National Chung Hsing University

梁重阳教授专注于重组蛋白大分子药物开发领域，多年从事药物作用机制相关结构生物学研究及理化分析工作，主导研发多项创新型单抗药物和亚单位疫苗，通过成果转化与企业合作推动管线在美国FDA和中国NMPA获批临床试验或上市。

胡颖

昭衍（苏州）新药研究中心有限公司，毒理二部主任

中国认证毒理学家（DCST），中国毒理学会生殖毒理专业委员会青年委员。本科和研究生曾就读于扬州大学兽医学院，硕士学位。从事药物毒理安全性评价工作14+，作为专题负责人完成550+项非临床毒理学研究，包括一般毒理、生殖和发育毒理、幼龄动物毒理试验、致癌性试验等。主要业务方向包括小分子化药、单克隆抗体/双特异性抗体、融合蛋白、多肽、疫苗、小核酸药物等。

Professor Linqi Zhang is the Director of the Comprehensive AIDS Research Center at Tsinghua University. Prof. Zhang's research focuses on HIV-1 pathogenesis and vaccine development, and has recently expanded to the field of emerging and re-emerging human viral pathogens such as SARS-CoV-1/2 and MERS-CoV. Using cutting-edge antibody and combinatorial antigen library techniques, Prof. Zhang’s research aims to characterize protective antibody immunity in infected humans and rational design of effective vaccines and therapies against the viral infection. Professor Zhang is the recipient of the National Outstanding Young Scientist Award, privileged Changjiang Professorship, and Bayer and Vanke Chair professor. He has published extensively and is among the most cited Chinese researchers in the field of microbiology and immunology. Professor Zhang has also served as a member of national expert and advisory board to the Chinese government and several international organizations on HIV/AIDS and infectious diseases,and was recently elected as a Foreign Fellow of the African Academy of Sciences.

-17年疫苗临床行业经验 n前广西疾控疫苗临床研究所所长（2010-2022），管理和实施过近300个临床试验，70+个疫苗临床试验PI，多个大型疫苗多中心效力试验leading PI。 

-CDE药审专家和国家专班专家，曾参与编著和讨论多个国家疫苗临床试验相关法规、技术指导原则，多次参加重大新药创制科技重大专项课题。 n曾作为PI主持：全球首个人二倍体细胞EV71灭活疫苗、国内首个mRNA新冠疫苗、HPV疫苗、轮状病毒疫苗、微卡、狂犬疫苗、IPV、bOPV、流感、肺炎疫苗、流脑疫苗等。 

-在国际期刊发表30+篇SCI论著，疫苗学第七版翻译编委、预防性疫苗临床试验设计与实施编委。 

-曾任国家局药品注册审评专家委员会委员、国务院联防联控机制科研攻关组疫苗研发专班专家组成员、国家免疫规划技术工作组成员、中华预防医学会疫苗临床专业委员会常委、原国家级和省级GCP检查员。

Dr. Tan is responsible for drug discovery, preclinical development, translation research and external collaboration in China. Dr. Tan got his Ph.D. in Molecular Medicine from UT Health Science Center San Antonio and received his Postdoctoral training with Dr. Michael Karin at UC San Diego. Dr. Tan worked in Pfizer and Novartis for 9 years, specialized in drug discovery and translational research, bridging preclinical research to early clinical trials. Dr. Tan worked at Biosion Biotech and Coherent Biopharma before he joined Clover. Dr. Tan was selected as Jiangsu Innovation and Entrepreneur Talent and Suzhou Innovation and Entrepreneur Leading Talent.

Dr. Shibo Jiang is a Professor at the Shanghai Institute of Infectious Disease and Biosecurity of Fudan University, Shanghai, China. His main research interest is the development of antiviral drugs and vaccines. He has published 572 papers (total IF: 7,662, average IF: 13.4) in SCI journals such as Cell (x3), Nature (x2), Science (x2), Lancet (x4), CNS’ sister journals (x71), with total 45,327 citations and an h-index of 105. He has applied for 104 patents, 54 of which were issued, and 11 of them were licensed out with 3 classes of innovative drugs and medical products used in clinics.

Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

Ruben Rizzi, physician by training, SVP of Global Regulatory Affairs at BioNTech. I joined the company in December 2019 just before the pandemic, and I have been the global regulatory lead for BioNTech for our COVID-19 development. Currently, I am still supporting the lifecycle of our COVID-19 vaccine, and I am co-leading the Global Regulatory Affairs department at BioNTech and working closely with the teams that are responsible for the development of BioNTech´s pipeline, post-approval activities and labelling

英博博士于2019年创立艾博生物，为公司创始人、董事长兼首席执行官。创立至今，艾博生物已建立起具有自主知识产权的mRNA和纳米递送技术平台，推动mRNA科学技术应用赋能创新医疗产品开发。

英博博士拥有国际化的行业视野和丰富的核酸药物开发领域工业界经验，精通RNA药物设计和纳米制剂产业化。创立艾博生物前，他曾在多家全球领先的核酸药物研发机构任核心研发团队负责人，领导开展包括小核酸（siRNA）、mRNA及基因编辑产品的开发及大规模工业化生产等工作。

英博博士本科、硕士毕业于复旦大学，并在美国东北大学获得药剂学博士学位。英博博士曾在Cell、Lancet等多个重要国际期刊发表论文，他也是多项海外授权专利发明人。2018-2019年期间，英博博士任波士顿美中生物医药协会（Chinese-American BioMedical Association）会长，服务生物医药科研和工业技术的深度融合。

陆汉新博士获乔治华盛顿大学遗传学博士学位，在生物医药产品开发领域拥有16年开拓性经验。他领导多学科团队推动治疗性与预防性疫苗技术平台创新，其开创性工作涵盖两大方向：开发针对高胆固醇血症等代谢紊乱及神经退行性病变的免疫治疗疫苗；设计新一代疫苗以应对呼吸道合胞病毒（RSV）、大流行流感、埃博拉病毒等新发传染性病原体。

陆博士的科学领导力贯穿疫苗研发全链条：从发现阶段的靶点验证、理性抗原设计及佐剂优化，到临床前开发的动物模型开发、机制研究与药效学分析，到生物标志物分层指导的I-III期临床试验，以及病毒学特性表征及符合GLP规范的疗效/安全性评估。

Doctor Hu is the founder, chairman and full-time CEO of Anda Biology. She was a former researcher of the Chinese Academy of Sciences Shanghai Institute of Nutrition and Health, visiting scholar of the Max-Planck-Institute for Molecular Genetics in Germany, and visiting scholar of the Cambridge Molecular Biology Laboratory in the UK. She independently undertook key projects of the National Natural Science Foundation of China and 863 projects as the project leader, participated in the Super 973 projects, the Chinese Academy of Sciences' Leading Special Research on Stem Cell and Regenerative Medicine, and the National Twelfth Five Year Plan Major Special Projects. Expert in the Second Review of Outstanding Youth Fund, Outstanding Youth Fund, and Key Projects of the National Natural Science Foundation of China, and expert in risk assessment of the Ministry of Science and Technology in 2013.

She has been engaged in molecular genetics research of diseases for a long time and has established a series of genetic analysis techniques that can be applied to stem cell clinical transformation research such as stem cell quality control, in vivo genetic tracing, stem cell maintenance, and cell phenotype transformation, laying the foundation for stem cell based disease diagnosis and treatment. Dr Hu has published more than 70 SCI papers and won the first prize for scientific and technological progress in Shanghai (second place completion).

She has participated as the leader of the innovation team in 2018 in the first Shenzhen Women's Innovation and Entrepreneurship Competition. After winning the award, she founded Anda Biology Medicine Development (Shenzhen) Co., Ltd and she is serving as its full-time CEO. In the past four years, she has led the company's employees to develop personalized immunotherapy vaccine for pancreatic cancer, universal cancer vaccines, cell therapy and other products. Among which, PCNAT-1, a therapeutic personalized vaccine for pancreatic cancer, has won the FDA orphan drug qualification certification.

Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.

Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant activity in late 1990s. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease. He served the president of Korean Vaccine Society (KVS) from 2013 to 2015. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of November 2023, he has more than 170 papers published in peer-reviewed journals and named as an inventor on 40 patents.

Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN.  Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.

Andrew Wong is a highly experienced professional with a strong background in biotech, vaccine development, and business management. Currently serving as the Senior Advisor to the Board of Directors at Walvax, Andrew has made significant contributions to the company's global operations.

Before taking on this advisory role, he was the General Manager of Shanghai Wotai Biotechnology Co., Ltd. from 2019, where he led a global team of over 50 professionals. His team was responsible for global vaccine registration, sales, marketing, technology transfer, and business development. Under his leadership, the team became one of China's leading vaccine export groups, expanding into 21 foreign markets such as Egypt, Morocco, Indonesia, and Thailand. His efforts led to a remarkable 25% compound annual growth rate in vaccine exports over the past five years.

Andrew's tenure at Walvax also includes an eight-year stint as Vice President of Corporate Strategy and Business Development at Shanghai Zerun Biotechnology Co., Ltd. From 2015 to 2020, he played a crucial role in securing major research and development grants, including a $7.5 million funding from the Bill and Melinda Gates Foundation for the development of HPV vaccines. Additionally, he was instrumental in securing R&D grants for Covid-19 vaccines, totaling $26 million from the Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI).

Andrew's academic background includes training in medicine and immunology (MSc) at West China Medical University (now Sichuan University), molecular biology (MSc) at the University of Manitoba, and an MBA from UCLA Anderson School of Management. His 30-year career includes about 12 years of experience at Amgen Inc., where he contributed to the development of recombinant antibody therapeutics and anticancer drugs. With his extensive experience in biotech, vaccine research, and global business development, Andrew Wong has been a driving force in Walvax’s global expansion and success in the vaccine market.

Rajinder as CEO-DCVMN International is responsible for leadership, governance, strategic vision and overall operational excellence of DCVMN.  Rajinder is appointed as member GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24, member PAVMs Talent Development WS and Regional Vaccine Manufacturing Collaborative (RVMC). To meet an un-precedented challenge posed by COVID-19, Rajinder has been actively involved in all global strategic initiatives along with COVAX partners-WHO, GAVI, CEPI, UNICEF and several other international organizations including industry associations to ensure equitable and timely access to vaccines. He has been member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group and Market Design and Demand Intelligence pillar of PAVM. Rajinder has over 25 years of top management experience in the industry including at the Board of Directors of the Indian subsidiary of Sanofi Pasteur and as CEO-Panacea Biotec. He has served as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee.

Peter Dull is the deputy director for Integrated Clinical Vaccine Development within the Global Health Division. In this role, he provides technical and strategic guidance on clinical development to the foundation’s program strategy teams, including Pneumonia and Enteric and Diarrheal Diseases, and external partners. In addition, he leads the foundation’s vaccine development activities for HPV vaccines, including efforts with reduced dose schedules.

Peter joined the foundation in 2014 after 10 years at Novartis Vaccines and Diagnostics where he was the clinical franchise head for Meningitis and Sepsis Vaccines. During that time, he led the clinical development and global licensure for a quadrivalent meningococcal glycoconjugate vaccine (Menveo; MenACWY-CRM) as well as a protein-based serogroup B meningococcal vaccine (Bexsero; 4CMenB). His work also included early clinical development of Group B strep glycoconjugate and Staph aureus vaccines. Prior to joining Novartis, he was an epidemic intelligence service officer in the Meningitis and Special Pathogens Branch at the U.S. Centers for Disease Control and completed subspecialty training in infectious diseases at Emory University.

He received his medical degree at University of Wisconsin-Madison and Internal Medicine training at Oregon Health Sciences University.

袁瑗女士是帕斯适宜卫生科技组织（PATH）上海代表处中国国家代表。她负责管理PATH与中国伙伴的合作关系，并为PATH在中国提供管理和业务发展支持。她于2007年1月加入PATH，担任过包括项目管理、行政财务官员等多项职务，在疫苗领域从业18年间，参与了乙脑疫苗世卫组织预认证、轮状疫苗开发、肺炎结合疫苗开发和培训、OPV海外临床、Sabin IPV D抗原国际标准制定、HPV疫苗预认证等项目，熟悉疫苗生命周期的生产、质量、临床、药政、药物警戒、生物安全等多个方面。2023年1月，袁瑗女士被选举为中国疫苗行业协会疫苗国际合作促进分会第一任秘书长。在加入PATH之前，她在新加坡Integrity Metals公司担任项目经理并在印尼工作。袁女士在北京大学获得文学学士、工商管理硕士和公共卫生硕士学位。

张骞，深圳康泰生物国际事业部总经理，中国疫苗行业协会疫苗国际合作促进分会委员，毕业于同济大学经管学院和法国ESSEC商学院，负责公司国际商务拓展、国际注册和国际合作工作。曾成功引进包括人二倍体细胞狂犬疫苗生产技术、灭活脊灰疫苗生产技术等多个核心疫苗生产技术。同时与多个新兴市场国家开展了产品海外商务拓展、注册和申报工作，已向东南亚、南亚、中东等国家出口部分产品的成品和中间产品，并正在推进在东南亚、南亚、中东、拉丁美洲、独联体、非洲等国家的成品注册、原液分装和技术转移工作。同时与驻华使领馆、跨国药企、国际研究所、国际组织等展开了丰富的交流与合作。

Ms Adel Sattarova holds Specialist Degree in Pharmacy. She has been working at the Saint Petersburg Scientific Research Institute of Vaccines and Serums (FSUE SPbSRIVS FMBA of Russia) since 2016 and currently holds a Head of Project Management Department position. Ms Adel Sattarova has an experience in regulatory affairs, leads the projects, one of which is the WHO prequalification of the influenza vaccine FLU-M® – the product developed and produced by FSUE SPbSRIVS FMBA of Russia with a production site in Saint Petersburg, Russia and Managua, Nicaragua.

Dr. Hun Kim is the President of Global Business at SK Bioscience. His role is to oversee the company's product and platform portfolio in a comprehensive perspective from R&D to commercialization through global alliance and external innovation.

Dr. Hun Kim started his biopharmaceutical career in 1992 as a researcher at Green Cross Corporation, In 2000, he moved on to Berna Biotech, a part of Crucell at present. In 2008, he joined SK Chemicals,the parent company of SK Bioscience, and lead the company's expansion in vaccine R&D, Quality and manufacturing capabilities.

Under his oversight, the company developed and received approval for cell culture-based influenza vaccines (SKYCellflu/SKYCellflu Quadrivalent), varicella/herpes zoster vaccines (SKYVaricella/SKYZoster),and Pneumococcal Conjugation Vaccines. During the Pandemic, it successfully manufactured and supplied COVID-19 vaccines developed by AstraZeneca and NovaVax. With support from CEPI and BMGF, SK Bioscience also developed its own COVID-19 vaccine (SKYCovione), which became the first domestically developed COVID-19 vaccine to be approved in Korea.

Melanie Saville, MBBS, is PATH’s Chief Scientific Officer. She leads PATH’s product development division, which includes a global team dedicated to the development, introduction, and scale of vaccines, medical devices, and diagnostics.

Dr. Saville is a distinguished physician specializing in virology with more than two decades of experience developing and licensing vaccines for global use. Her contributions over the past 20 years have included the development of vaccines for seasonal and pandemic influenza, as well as pediatric combinations and vaccines against rabies, Japanese encephalitis, dengue, Ebola, and SARS-CoV-2.

Before joining PATH, Dr. Saville worked with the Coalition for Epidemic Preparedness Innovations (CEPI), where she served as the Executive Director of Vaccine Research and Development, leading technical teams supporting vaccine development. She also served as the R&D and manufacturing workstream leader for COVAX, part of a global collaboration to speed development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

Dr. Saville holds a medical degree, a master’s degree in medical virology, and a Bachelor of Science in molecular biology from University College, London.

Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

Rita Carsetti trained in Medicine and Obstetrics and Gynecology at La Sapienza University of Rome (Italy) before discovering her passion for science during her postdoctoral training in the United States, at the M.D. Anderson Hospital in Houston (Texas). She followed this with a second postdoc at the Max-Plank Institute for Immunobiology in Freiburg (Germany), in the department of Georges Koehler, who had received the Nobel Prize for the discovery of monoclonal antibodies. At the Max-Planck she also became responsible for the flow cytometry core facility and later worked in the departments of Michael Reth and Thomas Boehm. After 13 years in Germany, she returned to Italy (Bambino Gesù Children’s Hospital, Rome) with a strong background in basic immunology of murine B cells. At this point she turned her attention to human B cells for a more patient-orientated research approach. The close contact with clinicians and her role as head of the Diagnostic Immunology Unit gave her the possibility to learn how human B cells change with age, immunodeficiency, infection, transplantation, and vaccination. The COVID-19 pandemic and the global vaccination campaign gave her the possibility to learn more about the development, function, and persistence of human memory B cells after vaccination in healthy subjects and patients with primary or secondary immunodeficiencies. Throughout her career, Rita Carsetti has made a number of discoveries regarding the development of human and murine B cell populations and the effect changes in such populations have on infection and immunodeficiencies in humans. Her recent work on SARS-CoV-2 and RNA vaccination has been vital in demonstrating how human memory B cells aid immune protection and how mucosal immunity is induced in neonates born to SARS-CoV-2 infected mothers. Altogether, Rita Carsetti’s work is extremely relevant to both basic and clinical immunologists.

Ph.D. in Molecular Virology from Wageningen University, the Netherlands. Formerly served as a researcher at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) in Canada, the Australian National University, and the University of Amsterdam, focusing on the molecular pathogenesis of influenza virus, respiratory syncytial virus, and baculovirus, as well as vaccine development for respiratory diseases. Currently employed at CanSino Biologics Inc. as a Senior Scientist in the R&D Center. Leading and driving major R&D projects and international collaborations within the company. As a project leader, working on the development of an inhaled adenovirus-vectored tuberculosis vaccine and dedicated to advancing mucosal vaccines and novel vaccine delivery technologies.

Hua Peng, Ph.D., Principal Investigator at the Guangzhou National laboratory (GNL). Dr. Hua Peng graduated from Peking University, Health Science Center with a bachelor's degree, and completed his doctoral and postdoctoral training in virology at the State University of New York at Buffalo and the National Institutes of Health (LVD/NIAID/NIH). Prior to joining GNL, Dr. Peng held positions as associate Prof./Prof./PI at the Institute of Biophysics, Chinese Academy of Sciences. Her research focuses on 1) Investigating host immune response to virus infection, viral pathogenic mechanism, and virus-associated malignancy; and 2) Developing innovative preventive and therapeutic vaccines against viral infections and immune based anti-cancer drugs. Dr. Hua Peng has made important scientific and translational achievements, publishing in prestigious journals including Gut, Cell Res., Sci Immun., JEM, JCI, Gastro, Nat Commun., PNAS, Nat Med, Nat Immun., Hepatology, Clin Can Res, JI, JBC, and JV. Prof. Peng’s team invented a new-generation SARS-CoV-2 recombinant vaccine, leading to the approval of the vaccine product V-01 and its iterative vaccine BV-01-QX for emergency use in collaboration with Livzon Bio.

魏霞蔚，四川大学华西医院研究员，博导，长江学者特聘教授，国家优秀青年基金获得者。 2010年毕业于浙江大学药物制剂系毕业获得学士学位，于四川大学华西药学院药剂系毕业获得博士学位。现任四川大学华西医院国际合作与交流办公室·港澳台事务办公室主任。任国家老年疾病临床医学中心副主任，华西医院老年与衰老医学研究室主任。任美国基因与细胞治疗协会分委会委员，任亚太地区基因/细胞治疗联盟青年主席。主要研究方向包括：重组蛋白疫苗与佐剂研发、鼻喷疫苗与新型疫苗递送系统、肺部炎性疾病与肿瘤免疫微环境研究、抗肿瘤小分子药物的转化研究等。在 Nature、Nature Communications、EMBO Molecular Medicine、Advanced Science、Molecular Cancer、ACS Nano等发表SCI论文，其中以通讯作者或第一发表SCI论文110篇(H-index=56)。担任4种SCI杂志的编委（Editorial Board Member）或副主编，获得2018年药明康德学者奖。

Dr. Chen has been a Professor at the State Key Lab of Respiratory Disease, Guangzhou Medical University since 2013. Dr. Chen received a medical degree from Shanghai Medical College in 1984. He obtained a Ph.D. in Biochemistry and Molecular Biology from Indiana University School of Medicine. Dr. Chen completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.  From 1997-2001, Dr. Chen served as a Senior Research Fellow at Merck Research Laboratories, where he was the first inventor of Merck's Ad5-based AIDS vaccine that entered clinical trials worldwide. Dr. Chen served as Vice President of R&D for GlaxoSmithKline in 2009-2011 and as Vice President at Sanofi Pasteur in 2012. Dr. Chen has over 200 publications in infectious diseases, vaccine research, and cancer research. His current research is focused on vaccine and antibody research on adenovirus, influenza virus, and emerging viruses. Since 2020, Dr. Chen has been working on developing user-friendly intranasal vaccines and mucosal immunity.

Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.

Christopher Gill has an MD from the University of Massachusetts Medical School and an MS from the Tufts School of Graduate Biomedical Studies.  Dr. Gill is an infectious disease specialist by training. From 2002-2008 and again from 2011-2023 he was a faculty member of the Department of Global Health at Boston University School of Public Health rising eventually to the level of full professor of Global Health.  During the intervening years 2008-11 he was the clinical director for the development of the MenACWY-CRM conjugate meningitis vaccine for Novartis Vaccines and Diagnostics. His work has centered broadly on child-survival in the areas of diarrheal diseases, pneumonia, and neonatal survival. However, his largest concentration of work has focused on better understanding the epidemiology of pediatric respiratory infections, notably Streptococcus pneumoniae, Bordetella pertussis and Respiratory Syncytial Virus.  At BU, Dr. Gill was the 2015 recipient of the Norman Scotch Award for excellence in teaching at Boston University School of Public Health, and the 2016 recipient of Boston University's Metcalf Cup and Prize. The Metcalf Cup and Prize is BU's highest teaching honor and is awarded to one of BU's >3500 faculty across its 17 colleges and schools each year.  At the Gates Foundation, Dr. Gill’s main areas are development of combination vaccines and expanding the impact of HPV vaccination globally. 

顾江，陆军军医大学国家免疫生物制品工程技术研究中心副主任、教授，博士生导师，国家重点研发计划首席科学家，“国防优才基金”获得者，军队高层次青年英才，陆军科技英才，陆军军医大学科研名师，享受军队优秀专业技术人才津贴。国家重点领域严重感染致病菌疫苗研发创新团队核心骨干；重庆英才创新创业示范团队核心骨干。中国疫苗行业协会细菌感染与疫苗研究专委会常委、秘书长，重庆微生物学会理事。先后获重庆市技术发明一等奖、军队科技进步二等奖等奖励。主要从事结构疫苗学基础与临床研究，围绕超级耐药菌的免疫干预展开，研制了1.1类新药——基因工程铜绿假单胞菌疫苗实现成果转化，合同金额2.8亿元。

Dr. Qiu has 20 years of experience in pharmaceutical development and alliance management.

Joining WuXi Vaccines in 2021, she is the Head of Alliance Management in charge of collaborating with global partners, establishing and expanding relationship with international organizations, and driving the global health initiatives.

Before joining WuXi Vaccines, she was the project leader in Schering Plough Research Institute and Novartis Pharmaceutical Corp. in US. In 2014, she joined WuXi AppTec as Director of Alliance Management and Program Management, managing key collaborations with MNCs and developed program strategy for its first ADC project. Later she established the proposal team in WuXi Biologics, which facilitated its rapid expansion in late stage and commercial business development. 

Graduated with a Ph.D. in Bioinformatics from the University of Science and Technology of China in 2014, under the guidance of Professor Liu Haiyan. Many years of experiences in molecular dynamics simulation and high-throughput sequencing, and have served as the Director of Bioinformatics for Micro Spin Genes and the Head of Nucleic Acid Drug Development for Yidu Cloud. Successfully developed multiple clinical high-throughput data analysis platforms and have authored multiple invention patent authorizations and SCI papers. As the co-founder of Therarna, responsible for identifying and optimizing upstream targets of mRNA drugs, leading the team to develop a systematic platform for identifying cross species cellular immune epitopes, designing humoral immune antigens, and optimizing mRNA sequences.

李浩，中国农业大学动物医学院副教授，博士生导师。2017年7月在清华大学获得理学博士学位。2017年7月到2019年7月在清华大学医学院从事博士后研究工作。2019年7月至今，在中国农业大学动物医学院从事结核病免疫学和抗生素耐药性相关研究。主持国自然面上和中国博士后基金各1项，国家重点研发计划研究任务1项，参与国自然3项。以第一或通讯作者（含共同）在Nature Reviews Immunology，PNAS，Nature Communications，npj Vaccines等杂志发表相关文章30余篇。

Markus is Head of Analytical Development, Microbiology, and Quality Control for the MAP-Program at LTS Lohmann Therapie Systeme AG in Andernach. He studied biology at Philipps University in Marburg, Germany, and was awarded a PhD in Parasitology in 2009 for his work on the membrane physiology and biochemistry of the Malaria parasite. From 2009 to 2015 he expanded his track record in infectious disease research at The Australian National University in Canberra, Australia. In 2015, he accepted a position for the University of Oxford, leading the Clinical Pharmacology laboratories at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok, Thailand. In 2019 he joined LTS as Head of Analytical Development, Microbiology and Quality Control for the MAP Program.

Mr. Lake has worked in vaccine manufacturing and commercialization for 30 years developing diverse experience at global leaders Merck and GlaxoSmithKline. Mr. Lake's background includes live virus and recombinant vaccine bulk production, sterile filling, and quality control, before moving into product management and business development roles. He served as the manufacturing Alliance Manager between Merck and Sanofi Pasteur during the startup of their European loint Venture and worked for several years as asenior level commercialization consultant in the vaccine industry.

Baik-Lin Seong, PhD, is a Distinguished Professor of Yonsei University College of Medicine, and Director General of Vaccine Innovative Technology ALliance (VITAL)-Korea. He received B.S. from Seoul National University (1977), M.S. from KAIST (1979), PhD from MIT (1988). He worked as postdoctoral scientist at the University of Oxford (1988-1992).

He served as a member of the Presidential Advisory Council of Science & Technology of Korean Government (2021-2022) and the Scientific Advisory Board of International Vaccine Institute (IVI) (2018-2022). He chaired the COVID-19 Vaccine Pan-Government Strategic Plan of the Korean Government (2020-2023).

With a view to ensure equitable access of effective vaccines to LMICs, he works on developing a low-cost production platform of VLP/nanoparticle vaccines against RSV, norovirus, nipah, universal influenza vaccine, and flavivirus vaccines including Japanese Encephalitis, Zika, and West Nile viruses.

Professor Adrian V. S. Hill FRS is the Director and Founder of the Jenner Institute, and Mital Professor of Vaccinology at Oxford University. He is a passionate believer in the power of molecular medicine to address many of the most egregious health care inequities globally. His group have been leaders in the development of adenoviral and other vaccines against infectious diseases and he has tested these in extensively in over eighty clinical trials in Africa and Europe. In partnership with the Serum Institute of India and AstraZeneca the Jenner Institute developed rapidly a ChAdOx1 vector-based SARS-CoV-2 vaccine which saved an estimated 6.2 million lives in 2021 alone.

His lab also designed a newly licensed high efficacy malaria vaccine, R21/Matrix-MTM, which has recently shown unprecedented high efficacy in a phase III trial in four African countries, again in partnership with the Serum Institute of India and also Novavax Inc. This vaccine promises to make a major impact on reducing the 500,000 childhood deaths from malaria each year. In 2021 he was elected a Fellow of the Royal Society and is a Knight Commander of the Order of the British Empire (KBE).

Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Lancet, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, the Young Scholar Award of Chinese Society of Immunology, and China Patent Silver Award Winner.

王寒，北京大学未来技术学院副研究员，疫苗研究团队负责人。主要从事病毒感染机制和抗病毒干预策略研究，在包括埃博拉病毒、猴痘病毒和非洲猪瘟病毒在内的多种重要病毒性传染病原的入侵和复制机制、疫苗、抗病毒药物研究中取得了一系列重要进展。以第一和通讯作者（含共同）在Cell、Nature Immunology、PNAS、Nucleic Acids Research等国际期刊上发表论文多篇，获“2016年度中国生命科学领域十大进展”。入选博士后创新人才支持计划、北京市科协“青年人才托举工程”、中国科学院青年创新促进会；任 hLife 期刊青年编委，北京慢性病防治与健康教育研究会感染性疾病专业委员会委员。